Molecular Imaging and Biology

, Volume 14, Issue 2, pp 183–196

In Vivo Imaging of Lymph Node Migration of MNP- and 111In-Labeled Dendritic Cells in a Transgenic Mouse Model of Breast Cancer (MMTV-Ras)

  • Cristina Martelli
  • Manuela Borelli
  • Luisa Ottobrini
  • Veronica Rainone
  • Anna Degrassi
  • Micaela Russo
  • Umberto Gianelli
  • Silvano Bosari
  • Carlo Fiorini
  • Daria Trabattoni
  • Mario Clerici
  • Giovanni Lucignani
Research Article

Abstract

Purpose

The authors present a protocol for the in vivo evaluation, using different imaging techniques, of lymph node (LN) homing of tumor-specific dendritic cells (DCs) in a murine breast cancer model.

Procedures

Bone marrow DCs were labeled with paramagnetic nanoparticles (MNPs) or 111In-oxine. Antigen loading was performed using tumor lysate. Mature DCs were injected into the footpads of transgenic tumor-bearing mice (MMTV-Ras) and DC migration was tracked by magnetic resonance imaging (MRI) and single-photon emission computed tomography (SPECT). Ex vivo analyses were performed to validate the imaging data.

Results

DC labeling, both with MNPs and with 111In-oxine, did not affect DC phenotype or functionality. MRI and SPECT allowed the detection of iron and 111In in both axillary and popliteal LNs. Immunohistochemistry and γ-counting revealed the presence of DCs in LNs.

Conclusions

MRI and SPECT imaging, by allowing in vivo dynamic monitoring of DC migration, could further the development and optimization of efficient anti-cancer vaccines.

Key words

Dendritic cells MRI SPECT In vivo imaging Vaccine protocol Breast cancer 

Abbreviations

DC

dendritic cell

DC-LAMP

dendritic cell-lysosomal associated membrane glycoprotein

FOV

field of view

GM-CSF

granulocyte macrophage colony-stimulating factor

iDC

immature DC

IL-4

interleukin-4

LN

lymph node

LPS

lipopolysaccharide

mDC

mature DC

MHC

major histocompatibility complex

MMTV

murine mammary tumor virus

MNPs

paramagnetic nanoparticles

MRI

magnetic resonance imaging

SDD

silicon drift detector

SPECT

single photon emission tomography

T2

transverse relaxation time

TE

echo time

TEM

transmission electron microscopy

TNFα

tumor necrosis factor α

TR

repetition time

Supplementary material

11307_2011_496_MOESM1_ESM.pdf (73 kb)
Fig. S1MNP labeling: dose–response and incubation-time study. a Relaxometric analysis of labeled cells in the dose–response study shows a decrease in T2 time, due to the presence of iron in the cells, that is proportional to the increase in the amount of iron used (R2 = 0.984). b Analysis of cell viability in the dose–response study by means of the Trypan Blue Exclusion Test shows that MNP labeling influences cell viability only for the highest dose (p < 0.01 vs ctrl). c Relaxometric analysis of labeled cells in the incubation-time study shows a decrease in T2 time, due to the presence of iron in the cells, in relation to the increase in the incubation time. The increase in T2 time at 48 h is probably a consequence of release of iron from dead cells (the dispersed, as opposed to clustered, MNPs in the cytoplasmic vesicles are associated with the formation of a weaker magnetic field, as described in the text [42]). d Analysis of cell viability in the incubation-time study by means of the Trypan Blue Exclusion Test shows that MNP labeling influences cell viability only for the longest incubation time (p < 0.01 vs ctrl) (PDF 73 kb)
11307_2011_496_MOESM2_ESM.pdf (68 kb)
Fig. S2Kinetics of DC migration to popliteal LNs, visualized by MRI and SPECT imaging. a MSME images and b SPECT imaging of MNP-labeled or 111In-labeled DCs, respectively, at popliteal LN level after DC injection into hind limb footpads. The hypointense signal can be detected 4 h after cell injection, and remains detectable at 24 and 48 h. In SPECT images, the dashed lines identify the field of view (FOV) of the SPECT instrument. The light blue arrows identify the injection site, and the dark blue arrows indicate the subiliac LN, where no signal was detected; K = kidneys (PDF 67 kb)
11307_2011_496_MOESM3_ESM.pdf (81 kb)
Fig. S3Kinetics of DC migration to axillary LNs, visualized by MRI and SPECT imaging. a FLASH images of MNP-labeled DCs at accessory axillary LN level after DC injection into forelimb footpads. The hypointense signal can be detected 24 h after cell injection, and is still detectable at 48 h. No iron signal can be observed in the LNs before cell injection (white arrows). b SPECT imaging of 111In-labeled DCs at the level of both axillary LNs after DC injection into forelimb footpads. The hypointense signal can be detected 4 h after cell injection, and is still detectable at 24 h. At 48 h the signal is no longer visible due to radiotracer decay, as can be observed at the level of the injection site. In SPECT images, the dashed lines identify the field of view (FOV) of the SPECT instrument (PDF 81 kb)
11307_2011_496_MOESM4_ESM.pdf (122 kb)
Fig. S4Perl’s staining demonstrates, in the collected LNs, the presence of iron in the cytoplasm of migrated cells. Consecutive optical enlargement of Perl’s staining in LNs showed that labeled cells localized in the cortical and paracortical areas of the lymph nodes. In the control LNs (untreated), we observed no presence of iron (PDF 121 kb)

References

  1. 1.
    Tuyaerts S, Aerts JL, Corthals J et al (2007) Current approaches in dendritic cell generation and future implications for cancer immunotherapy. Cancer Immunol Immun 56(10):1513–1537Google Scholar
  2. 2.
    Nouri-Shirazi M, Banchereau J, Fay J, Palucka K (2000) Dendritic cell based tumor vaccines. Immunol Lett 74(1):5–10PubMedCrossRefGoogle Scholar
  3. 3.
    Wan H, Dupasquier M (2005) Dendritic cells in vivo and in vitro. Cell Mol Immunol 2(1):28–35PubMedGoogle Scholar
  4. 4.
    Mosca PJ, Lyerly HK, Clay TM, Morse MA, Lyerly HK (2007) Dendritic cell vaccines. Front Biosci 12:4050–4060PubMedCrossRefGoogle Scholar
  5. 5.
    Maldonado-Lopez R, Moser M (2001) Dendritic cell subsets and the regulation of Th1/Th2 responses. Semin Immunol 13(5):275–282PubMedCrossRefGoogle Scholar
  6. 6.
    Lanzavecchia A, Sallusto F (2001) Regulation of T cell immunity by dendritic cells. Cell 106(3):263–266PubMedCrossRefGoogle Scholar
  7. 7.
    Yu JS, Liu G, Ying H et al (2004) Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 64(14):4973–4979PubMedCrossRefGoogle Scholar
  8. 8.
    Svane IM, Pedersen AE, Johansen JS et al (2007) Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers. Cancer Immunol Immunother 56(9):1485–1499PubMedCrossRefGoogle Scholar
  9. 9.
    Mittendorf EA, Storrer CE, Foley RJ et al (2006) Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial. Cancer 106(11):2309–2317PubMedCrossRefGoogle Scholar
  10. 10.
    Katano M, Morisaki T, Koga K et al (2005) Combination therapy with tumor cell-pulsed dendritic cells and activated lymphocytes for patients with disseminated carcinomas. Anticancer Res 25(6A):3771–3776PubMedGoogle Scholar
  11. 11.
    Guardino AE, Rajapaksa R, Ong KH, Sheehan K, Levy R (2006) Production of myeloid dendritic cells (DC) pulsed with tumor-specific idiotype protein for vaccination of patients with multiple myeloma. Cytotherapy 8(3):277–289PubMedCrossRefGoogle Scholar
  12. 12.
    Ovali E, Dikmen T, Sonmez M et al (2007) Active immunotherapy for cancer patients using tumor lysate pulsed dendritic cell vaccine: a safety study. J Exp Clin Cancer Res 26(2):209–214PubMedGoogle Scholar
  13. 13.
    Kyte JA, Mu L, Aamdal S et al (2006) Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA. Cancer Gene Ther 13(10):905–918PubMedCrossRefGoogle Scholar
  14. 14.
    Palucka AK, Ueno H, Connolly J et al (2006) Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. J Immunother 29(5):545–557PubMedCrossRefGoogle Scholar
  15. 15.
    Ridolfi R, Riccobon A, Galassi R et al (2004) Evaluation of in vivo labelled dendritic cell migration in cancer patients. J Transl Med 2:27PubMedCrossRefGoogle Scholar
  16. 16.
    Quillien V, Moisan A, Carsin A et al (2005) Biodistribution of radiolabelled human dendritic cells injected by various routes. Eur J Nucl Med Mol Imaging 32(7):731–741PubMedCrossRefGoogle Scholar
  17. 17.
    Gilboa E (2007) DC-based cancer vaccines. J Clin Invest 117(5):1195–1203PubMedCrossRefGoogle Scholar
  18. 18.
    Cerundolo V, Hermans IF, Salio M (2004) Dendritic cells: a journey from laboratory to clinic. Nat Immunol 5(1):7–10PubMedCrossRefGoogle Scholar
  19. 19.
    Timmerman JM, Levy R (1999) Dendritic cell vaccines for cancer immunotherapy. Annu Rev Med 50:507–529PubMedCrossRefGoogle Scholar
  20. 20.
    Lucignani G, Ottobrini L, Martelli C, Rescigno M, Clerici M (2006) Molecular imaging of cell-mediated cancer immunotherapy. Trends Biotechnol 24(9):410–418PubMedCrossRefGoogle Scholar
  21. 21.
    De Vries IJM, Lesterhuis WJ, Barentsz JO et al (2005) Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol 23(11):1407–1413PubMedCrossRefGoogle Scholar
  22. 22.
    Lutz MB, Kukutsch N, Ogilvie ALJ et al (1999) An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Meth 223:77–92CrossRefGoogle Scholar
  23. 23.
    Baumjohann D, Hess A, Budinsky L et al (2006) In vivo magnetic resonance imaging of DC migration into the draining lymph nodes of mice. Eur J Immunol 36:2544–2555PubMedCrossRefGoogle Scholar
  24. 24.
    Baumjohann D, Hess A, Budinsky L et al (2006) Non-invasive imaging of dendritic cell migration in vivo. Immunobiology 211:587–597PubMedCrossRefGoogle Scholar
  25. 25.
    Bhirde A, Xie J, Swierczewska M, Chen X (2011) Nanoparticles for cell labeling. Nanoscale 3:142–153PubMedCrossRefGoogle Scholar
  26. 26.
    Cheng D, Hong G, Wang W et al (2011) Nonclustered magnetite nanoparticle encapsulated biodegradable polymeric micelles with enhanced properties for in vivo tumor imaging. J Mater Chem 21:4796–4804CrossRefGoogle Scholar
  27. 27.
    Taneja P, Frazier DP, Kending RD et al (2009) MMTV mouse models and the diagnostic values of MMTV-like sequences in human breast cancer. Expert Rev Mol Diagn 9(5):423–440PubMedCrossRefGoogle Scholar
  28. 28.
    Pattengale PK, Stewart TA, Leder A et al (1989) Animal models of human disease. Pathology and molecular biology of spontaneous neoplasm occurring in transgenic mice carrying and expressing activated cellular oncogenes. Am J Pathol 135(1):39–61PubMedGoogle Scholar
  29. 29.
    Huang AL, Ostrowski MC, Berard D, Hager G (1981) Glucocorticoid regulation of the Ha-MuSV p 21 gene conferred by sequences from mouse mammary tumor virus. Cell 27:245–255PubMedCrossRefGoogle Scholar
  30. 30.
    Zappi E, Lombardo W (1984) Combined Fontana–Massono/Perl’s staining. Am J Dermatophat 6(suppl):143–145Google Scholar
  31. 31.
    Boutry S, Brunin S, Mahieu I et al (2008) Magnetic labeling of non-phagocytic adherent cells with iron oxide nanoparticles: a comprehensive study. Contrast Media Mol Imaging 3(6):223–232PubMedCrossRefGoogle Scholar
  32. 32.
    Montet-Abou K, Montet X, Weissleder R, Josephson L (2007) Cell internalization of magnetic nanoparticles using transfection agents. Mol Imaging 6(1):1–9PubMedGoogle Scholar
  33. 33.
    Qiu J, Li GW, Sui YF et al (2006) Heat-shocked tumor cell lysate-pulsed dendritic cells induce effective anti-tumor immune response in vivo. World J Gastroenterol 12(3):473–478PubMedGoogle Scholar
  34. 34.
    Van den Broeck W, Derore A, Simoens P (2006) Anatomy and nomenclature of murine lymph nodes: Descriptive study and nomenclatory standardization in BALB/cAnNCrl mice. J Immunol Meth 312:12–19CrossRefGoogle Scholar
  35. 35.
    Kosaka N, Ogawa M, Sato N, Choyke PL, Kobayashi H (2009) In vivo real-time, multicolor, quantum dot lymphatic imaging. J Invest Dermatol 129:2818–2822PubMedCrossRefGoogle Scholar
  36. 36.
    Poli GL, Fiorini C, Gola A et al (2009) The HICAM project: development of a High- Resolution Gamma Camera. 9th National Congress of the Italian Association of Nuclear Medicine and Molecular Imaging (AIMN), March 20–24, 2009, Florence Italy, published on the Q J Nucl Med Mol Imaging 53 (suppl. 1 to issue 2)Google Scholar
  37. 37.
    Fiorini C, Gola A, Peloso R et al (2010) The DRAGO gamma camera. Rev Sci Instrum 81:44301–44307CrossRefGoogle Scholar
  38. 38.
    Verdijk P, Scheenen TWJ, Lesterhuis WJ et al (2006) Sensitivity of magnetic resonance imaging of dendritic cells for in vivo tracking of cellular cancer vaccines. Int J Cancer 120:978–984CrossRefGoogle Scholar
  39. 39.
    Gratton SE, Ropp PA, Pohlhaus PD et al (2008) The effect of particle design on cellular internalization pathways. Proc Natl Acad Sci USA 105(33):11613–11618PubMedCrossRefGoogle Scholar
  40. 40.
    Dobrovolskaia MA, Aggarwal P, Hall JE, McNeil SE (2008) Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol Pharmaceut 5(4):487–495CrossRefGoogle Scholar
  41. 41.
    Kellerman SA, Hudak S, Oldham ER, Liu YJ, Mcevoy LM (1999) The CC chemokine receptor-7 ligands 6Ckine and macrophage inflammatory protein-3β are potent chemoattractants for in vitro and in vivo-derived dendritic cells. J Immunol 162:3859–3864Google Scholar
  42. 42.
    Lewin M, Carlesso N, Tung CH et al (2000) Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat Biotechnol 18:410–414PubMedCrossRefGoogle Scholar
  43. 43.
    Ahrens ET, Feili-Hariri M, Xu H, Genove G, Morel PA (2003) Receptor-mediated endocytosis of iron-oxide particles provides efficient labeling of dendritic cells for in vivo MR imaging. Magn Reson Med 49:1006–1013PubMedCrossRefGoogle Scholar
  44. 44.
    Yigit MV, Mazumdar D, Kim HK, Lee JH, Odintsov B, Lu Y (2007) Smart “turn-on” magnetic resonance contrast agents based on aptamer-functionalized superparamagnetic iron oxide nanoparticles. Chembiochem 8:1675–1678PubMedCrossRefGoogle Scholar
  45. 45.
    Josephson L, Kircher MF, Mahmood U, Tang Y, Weissleder R (2002) near-infrared fluorescent nanoparticles as combined MR/optical imaging probes. Bioconjug Chem 13:554–560PubMedCrossRefGoogle Scholar
  46. 46.
    Zhiyong W, Gang L, Jiayu S et al (2009) Self-assembly of magnetite nanocrystals with amphiphilic polyethylenimine: structures and applications in magnetic resonance imaging. J Nanosci Nanotechnol 9:378–385CrossRefGoogle Scholar
  47. 47.
    Benderbous S, Corot C, Jacobs P, Bonnemain B (1996) Superparamagnetic agents: physicochemical characteristics and preclinical imaging evaluation. Acad Radiol 3(Suppl 2):S292–S294PubMedCrossRefGoogle Scholar
  48. 48.
    Issekutz T, Chin W, Hay JB (1980) Measurement of lymphocyte traffic with indium-111. Clin Exp Immunol 39(1):215–221PubMedGoogle Scholar
  49. 49.
    Lanzavecchia A, Sallusto F (2001) The instructive role of dendritic cells on T cell responses: lineages, plasticity and kinetics. Curr Opin Immunol 31:291–298CrossRefGoogle Scholar
  50. 50.
    Dodd SJ, Williams M, Suhan JP et al (1999) Detection of single mammalian cells by high-resolution magnetic resonance imaging. Biophys J 76(1 pt 1):103–109PubMedCrossRefGoogle Scholar
  51. 51.
    Kobukai S, Baheza R, Cobb JG et al (2010) Magnetic nanoparticles for imaging dendritic cells. Magn Reson Med 63:1383–1390PubMedCrossRefGoogle Scholar
  52. 52.
    Pham W, Kobukai S, Hotta C, Gore JC (2009) Dendritic cells; therapy and imaging. Exp Opin Biol Ther 9(5):539–564CrossRefGoogle Scholar
  53. 53.
    Briley-Saebo K, Leboeuf M, Dickson S et al (2010) Longitudinal tracking of human dendritic cells in murine models using magnetic resonance imaging. Magn Reson Med 64:1510–1519PubMedCrossRefGoogle Scholar
  54. 54.
    Helfer BM, Balducci A, Nelson AD et al (2010) Functional assessment of human dendritic cells labeled for in vivo 19F magnetic resonance imaging cell tracking. Cytotherapy 12:238–250PubMedCrossRefGoogle Scholar
  55. 55.
    Rohani R, de Chickera SN, Willert C et al (2010) In vivo cellular MRI or dendritic cell migration using micrometer-sized iron oxide (MPIO) particles. Mol Imaging Biol. doi:10.1007/s11307-010-0403-0
  56. 56.
    Allan RS, Waithman J, Bedoui S et al (2006) Migratory dendritic cells transfer antigen to a lymph node-resident dendritic cell population for efficient CTL priming. Immunity 25:153–162PubMedCrossRefGoogle Scholar

Copyright information

© Academy of Molecular Imaging and Society for Molecular Imaging 2011

Authors and Affiliations

  • Cristina Martelli
    • 1
    • 2
  • Manuela Borelli
    • 3
  • Luisa Ottobrini
    • 1
    • 2
  • Veronica Rainone
    • 3
  • Anna Degrassi
    • 4
  • Micaela Russo
    • 4
  • Umberto Gianelli
    • 5
  • Silvano Bosari
    • 5
  • Carlo Fiorini
    • 6
  • Daria Trabattoni
    • 3
  • Mario Clerici
    • 2
    • 7
    • 8
  • Giovanni Lucignani
    • 1
    • 2
  1. 1.Department of Biomedical Sciences and Technologies, Section of Radiological SciencesUniversity of MilanMilanItaly
  2. 2.Centre of Molecular and Cellular Imaging – IMAGOUniversity of MilanSegrateItaly
  3. 3.Department of Clinical Sciences, Chair of ImmunologyUniversity of MilanMilanItaly
  4. 4.Pharmacology Department, BU OncologyNerviano Medical SciencesNervianoItaly
  5. 5.Pathology Unit, Department of Medicine, Surgery and DentistryUniversity of Milan Medical School, IRCCS Ca’ Granda – Ospedale Maggiore Policlinico FoundationMilanItaly
  6. 6.Electronic and Information Technology DepartmentPolitecnico di MilanoMilanItaly
  7. 7.Department of Biomedical Sciences and TechnologiesUniversity of MilanSegrateItaly
  8. 8.IRCCS Don C. Gnocchi FoundationMilanItaly

Personalised recommendations